Literature DB >> 23541680

Oxidation-specific epitopes and immunological responses: Translational biotheranostic implications for atherosclerosis.

Gregor Leibundgut1, Joseph L Witztum, Sotirios Tsimikas.   

Abstract

Oxidation-specific epitopes (OSE), present on oxidized LDL (OxLDL), apoptotic cells, cell debris and modified proteins in the vessel wall, accumulate in response to hypercholesterolemia, and generate potent pro-inflammatory, disease-specific antigens. They represent an important class of 'danger associated molecular patterns' (DAMPs), against which a concerted innate immune response is directed. OSE are recognized by innate 'pattern recognition receptors', such as scavenger receptors present on dendritic cells and monocyte/macrophages, as well as by innate proteins, such as IgM natural antibodies and soluble proteins, such as C-reactive protein and complement factor H. These innate immune responses provide a first line of defense against atherosclerosis-specific DAMPs, and engage adaptive immune responses, provided by T and B-2 cells, which provide a more specific and definitive response. Such immune responses are ordinarily directed to remove foreign pathogens, such as those found on microbial pathogens, but when persistent or maladaptive, lead to host damage. In this context, atherosclerosis can be considered as a systemic chronic inflammatory disease initiated by the accumulation of OSE type DAMPs and perpetuated by maladaptive response of the innate and adaptive immune system. Understanding this paradigm leads to new approaches to defining cardiovascular risk and suggests new modes of therapy. Therefore, OSE have become potential targets of diagnostic and therapeutic agents. Human and murine OSE-targeting antibodies have been developed and are now being used as biomarkers in human studies and experimentally in translational applications of non-invasive molecular imaging of oxidation-rich plaques and immunotherapeutics.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23541680      PMCID: PMC3844667          DOI: 10.1016/j.coph.2013.02.005

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  72 in total

1.  IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis.

Authors:  Christoph J Binder; Karsten Hartvigsen; Mi-Kyung Chang; Marina Miller; David Broide; Wulf Palinski; Linda K Curtiss; Maripat Corr; Joseph L Witztum
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

2.  Oxidized low-density lipoprotein and atherosclerosis.

Authors:  Daniel Steinberg; Joseph L Witztum
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-12       Impact factor: 8.311

Review 3.  Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events.

Authors:  Adam Taleb; Joseph L Witztum; Sotirios Tsimikas
Journal:  Biomark Med       Date:  2011-10       Impact factor: 2.851

Review 4.  Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications.

Authors:  Ira Tabas; Kevin Jon Williams; Jan Borén
Journal:  Circulation       Date:  2007-10-16       Impact factor: 29.690

5.  Toll-like receptor 4-dependent and -independent cytokine secretion induced by minimally oxidized low-density lipoprotein in macrophages.

Authors:  Yury I Miller; Suganya Viriyakosol; Dorothy S Worrall; Agnès Boullier; Susan Butler; Joseph L Witztum
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-02-17       Impact factor: 8.311

6.  Atherosclerosis induced by endogenous and exogenous toll-like receptor (TLR)1 or TLR6 agonists.

Authors:  Linda K Curtiss; Audrey S Black; David J Bonnet; Peter S Tobias
Journal:  J Lipid Res       Date:  2012-07-20       Impact factor: 5.922

Review 7.  Macrophage death and defective inflammation resolution in atherosclerosis.

Authors:  Ira Tabas
Journal:  Nat Rev Immunol       Date:  2009-12-04       Impact factor: 53.106

Review 8.  Innate and adaptive immunity in atherosclerosis.

Authors:  René R S Packard; Andrew H Lichtman; Peter Libby
Journal:  Semin Immunopathol       Date:  2009-05-16       Impact factor: 9.623

9.  Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study.

Authors:  Stefan Kiechl; Johann Willeit; Manuel Mayr; Brigitte Viehweider; Martin Oberhollenzer; Florian Kronenberg; Christian J Wiedermann; Sabine Oberthaler; Qingbo Xu; Joseph L Witztum; Sotirios Tsimikas
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-05-31       Impact factor: 8.311

10.  Peptide mimotopes of malondialdehyde epitopes for clinical applications in cardiovascular disease.

Authors:  Shahzada Amir; Karsten Hartvigsen; Ayelet Gonen; Gregor Leibundgut; Xuchu Que; Erika Jensen-Jarolim; Oswald Wagner; Sotirios Tsimikas; Joseph L Witztum; Christoph J Binder
Journal:  J Lipid Res       Date:  2012-04-16       Impact factor: 5.922

View more
  35 in total

Review 1.  Oxidation-specific epitopes as targets for biotheranostic applications in humans: biomarkers, molecular imaging and therapeutics.

Authors:  Yury I Miller; Sotirios Tsimikas
Journal:  Curr Opin Lipidol       Date:  2013-10       Impact factor: 4.776

2.  Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial.

Authors:  Young Sup Byun; Jun-Hee Lee; Benoit J Arsenault; Xiaohong Yang; Weihang Bao; David DeMicco; Rachel Laskey; Joseph L Witztum; Sotirios Tsimikas
Journal:  J Am Coll Cardiol       Date:  2015-04-07       Impact factor: 24.094

3.  The NLRP3 and CASP1 gene polymorphisms are associated with developing of acute coronary syndrome: a case-control study.

Authors:  Hector Gonzalez-Pacheco; Gilberto Vargas-Alarcon; Javier Angeles-Martinez; Carlos Martinez-Sanchez; Oscar Perez-Mendez; Gabriel Herrera-Maya; Marco Antonio Martinez-Rios; Marco Antonio Peña-Duque; Carlos Posadas-Romero; Jose Manuel Fragoso
Journal:  Immunol Res       Date:  2017-08       Impact factor: 2.829

Review 4.  Pathophysiology and Treatments of Oxidative Injury in Ischemic Stroke: Focus on the Phagocytic NADPH Oxidase 2.

Authors:  Federico Carbone; Priscila Camillo Teixeira; Vincent Braunersreuther; François Mach; Nicolas Vuilleumier; Fabrizio Montecucco
Journal:  Antioxid Redox Signal       Date:  2014-04-22       Impact factor: 8.401

5.  Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans.

Authors:  Fleur M van der Valk; Siroon Bekkering; Jeffrey Kroon; Calvin Yeang; Jan Van den Bossche; Jaap D van Buul; Amir Ravandi; Aart J Nederveen; Hein J Verberne; Corey Scipione; Max Nieuwdorp; Leo A B Joosten; Mihai G Netea; Marlys L Koschinsky; Joseph L Witztum; Sotirios Tsimikas; Niels P Riksen; Erik S G Stroes
Journal:  Circulation       Date:  2016-08-05       Impact factor: 29.690

6.  Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a).

Authors:  Gregor Leibundgut; Corey Scipione; Huiyong Yin; Matthias Schneider; Michael B Boffa; Simone Green; Xiaohong Yang; Edward Dennis; Joseph L Witztum; Marlys L Koschinsky; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2013-07-04       Impact factor: 5.922

7.  Acute and long-term effect of percutaneous coronary intervention on serially-measured oxidative, inflammatory, and coagulation biomarkers in patients with stable angina.

Authors:  Gregor Leibundgut; Jun-Hee Lee; Bradley H Strauss; Amit Segev; Sotirios Tsimikas
Journal:  J Thromb Thrombolysis       Date:  2016-05       Impact factor: 2.300

Review 8.  Imaging of oxidation-specific epitopes with targeted nanoparticles to detect high-risk atherosclerotic lesions: progress and future directions.

Authors:  Karen Briley-Saebo; Calvin Yeang; Joseph L Witztum; Sotirios Tsimikas
Journal:  J Cardiovasc Transl Res       Date:  2014-10-09       Impact factor: 4.132

Review 9.  Oxidized cholesteryl esters and inflammation.

Authors:  Soo-Ho Choi; Dmitri Sviridov; Yury I Miller
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2016-06-29       Impact factor: 4.698

10.  New therapeutic targets for calcific aortic valve stenosis: the lipoprotein(a)-lipoprotein-associated phospholipase A2-oxidized phospholipid axis.

Authors:  Ming-Yow Hung; Joseph L Witztum; Sotirios Tsimikas
Journal:  J Am Coll Cardiol       Date:  2013-10-23       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.